1. Sawatzky J, Conroy AL, Brochon J, Kakkar F, et al.
   Dysregulation of circulating angiopoietins is associated with low birth weight in children who are HIV-exposed and uninfected.
   AIDS 2026;40:696-699.
   


2. Rubin LH, Maki PM, Du Y, Dastgheyb RM, et al.
   Stability of the translocator protein 18 kDa density within cognitive circuits in brains of virally-suppressed people with HIV.
   AIDS 2026;40:693-696.
   


3. Bono V, Tincati C, Augello M, Rovito R, et al.
   Age and viral replication, not vertical HIV acquisition, drive inflammation and T-cell dysfunction in heavily treatment experienced: data from the Prestigio Registry.
   AIDS 2026;40:690-693.
   


4. Kekitiinwa AR, Juma M, Tumusiime C, Ssebunya RN, et al.
   Integrating tuberculosis services with the Orphans and Vulnerable Children Program in Rwenzori region, Uganda, 2022-2023.
   AIDS 2026.
   


5. Cromhout GZ, Bengu N, Herbert NG, Fillis R, et al.
   Increases in total HIV-1 nucleic acid in whole blood precede plasma rna rebound during paediatric analytical treatment interruption.
   AIDS 2026.
   


6. Lahiri CD, Soibi-Harry AP, Musonge-Effoe J, Alvarez JA, et al.
   Association between plasma concentrations of integrase strand transfer inhibitors and body weight gain in women living with HIV.
   AIDS 2026.
   


7. Aizire KJ, Lewis L, Pettifor JM, Atuhaire P, et al.
   Bone turnover marker trajectories in postpartum women living with HIV compared to women without HIV.
   AIDS 2026.
   


8. Hwang YJ, Lesko CR, Brown TT, Alexander GC, et al.
   Changes in weight and glycemia after initiation of integrase strand transfer inhibitors among people with HIV and diabetes in the United States and Canada.
   AIDS 2026.
   


9. Chalouni M, Torgersen J, Rentsch CT, Van Santen DK, et al.
   Risk of type 2 diabetes mellitus after treatment with direct-acting antivirals for Hepatitis C virus in people with HIV.
   AIDS 2026.
   


10. Mete Atasever N, Dede E, Yilmaz S, Akkoc G, et al.
    Meningococcal and pneumococcal carriage in children living with HIV: a multi-center prospective study from Turkiye (MENPHIV-TR study).
    AIDS 2026.
    


11. McFarlane WJ, Brogly SB, Flemming JA, Martinez-Cajas J, et al.
    HIV-sex interaction effect on risk of hepatitis C-related cirrhosis, decompensation, and hepatocellular carcinoma.
    AIDS 2026.
    


12. Guilamo-Ramos V, Thimm-Kaiser M, Benzekri A, Stafford SR, et al.
    The price of invisibility: a cascading disaster in the US Latino HIV epidemic.
    AIDS 2026.
    


13. Aung HL, Patel P, Gray RT, Asselin J, et al.
    Sustained viral suppression among people living with HIV in the era of Undetectable = Untransmittable (U = U) in Australia.
    AIDS 2026.
    


14. Chen T, Chen X, Wang S, Wang L, et al.
    Male-specific association of HIV infection with lower risk of hyperuricemia is mediated by lower BMI and AGR.
    AIDS 2026.
    


15. Pennetzdorfer N, Naik V, Montezuma-Rusca JM, Sklar P, et al.
    Baseline and week 48 resistance analysis in participants receiving bictegravir + lenacapavir in the phase 2 ARTISTRY-1 study.
    AIDS 2026.
    


16. Kwok M, Dandapani H, Ibrahim N, Bloomfield GS, et al.
    Estimating the degree of cardiovascular disease risk under-prediction in people living with HIV by existing risk models: an updated meta-analysis.
    AIDS 2026.
    


17. Bailin SS, Gabriel CL, Gangula RD, Hannah L, et al.
    Adipose tissue microvascular is linked to insulin resistance and lipidome alterations in treated HIV.
    AIDS 2026.
    


18. Chida N.
    Staying in the Tent: Why Infectious Disease Physicians Remain Essential to Human Immunodeficiency Virus Primary Care.
    Clin Infect Dis 2026.
    


19. Graber CJ, Landovitz RJ, Branch-Elliman W.
    Providing the Best Infectious Diseases and Primary Care to Our Patients With HIV: Time for Delivery Models to Evolve.
    Clin Infect Dis 2026.
    


20. Menza TW, Berzkalns A, Cannon CA, Balkus J, et al.
    The population-level impact of doxycycline post-exposure prophylaxis on syphilis in King County, WA: an interrupted time series analysis.
    Clin Infect Dis 2026.
    


21. McManus KA, Killelea A, Rogers EQ, Liu F, et al.
    State AIDS Drug Assistance Programs' Contribution to the US Viral Suppression, 2015-2022.
    Clin Infect Dis 2026.
    


22. Linas BP.
    Centering AIDS Drug Assistance Programs in the US HIV Response.
    Clin Infect Dis 2026.
    


23. VanderVeen LA, Selzer L, Chang S, Li J, et al.
    Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People with HIV at 48 Weeks.
    J Acquir Immune Defic Syndr 2026.
    


24. Bodley N, Govender K, Moodley P, Samsunder N, et al.
    Association between pharmacological tenofovir adherence measures and subsequent 24-week viral load outcomes for people with HIV in South Africa.
    J Acquir Immune Defic Syndr 2026.
    


25. Kalichman SC.
    Response to Mahida and Jagtap's Comment on "Dose Determination Trial for Evidence-Based Behavioral Counseling to Improve HIV Care Engagement and Treatment Adherence".
    J Acquir Immune Defic Syndr 2026.
    


26. Laeremans T, den Roover S, Nezic SJ, Allard SD, et al.
    Proteasome Inhibition Reactivates Latent HIV-1 and Boosts NK Cell Killing via HLA-E Downregulation.
    J Med Virol 2026;98:e70895.
    


27. Pita-Martinez C, Munoz-Garcia P, Martinez I, Rava M, et al.
    Elevated Zonulin-1 is Associated With an Increased Risk of Non-AIDS-Defining Cancers in People With HIV With Suboptimal Immune Recovery: A Case-Cohort Study.
    J Med Virol 2026;98:e70884.
    


28. Pan D, Choi JS, Choi MJ, Phillips R, et al.
    Respiratory virus research needs its own PPIE.
    Lancet 2026;407:1144-1145.
    

Display articles in

• Abstract format